How is E. coli infection treated?

Escherichia coli (E. coli) infections are a significant health concern and can manifest in various forms such as urinary tract infections, respiratory infections, and gastrointestinal diseases. Treatment strategies for E. coli infections vary depending on the type of infection and the resistance patterns of the bacteria.

Non-pathogenic strains of E. coli can be used to maintain remission in ulcerative colitis, suggesting a potential therapeutic role for certain E. coli strains in this condition.
Immunomodulation and antigen therapy have shown effectiveness in treating E. coli infections of the lower urinary tract in animal models, indicating a possible avenue for treatment in humans.
Oral antibiotics such as fosfomycin, pivmecillinam, and nitrofurantoin are important treatment options for urinary tract infections caused by extended-spectrum-β-lactamase (ESBL)-producing E. coli.
Bacteriophage therapy has been effective in treating severe E. coli respiratory infections in animal studies, suggesting a potential alternative to traditional antibiotics.
Antibiotics like chloramphenicol and neomycin sulfate have been used to treat E. coli diarrheal disease, with neomycin sulfate effectively eradicating the pathogen from stool cultures.
The emergence of fluoroquinolone-resistant E. coli has implications for prophylaxis and treatment of post-prostate biopsy infections, necessitating alternative antibiotics such as cephalosporins until culture results are available.
Antibiotic resistance patterns in E. coli from sewage and sludge highlight the importance of monitoring resistance and tailoring treatment accordingly.
For community-acquired infections, fosfomycin and amoxicillin-clavulanate are effective against cystitis caused by ESBL-producing E. coli, provided the isolates are susceptible.
Colistin has been used to treat nosocomial infections caused by multidrug-resistant E. coli, although renal failure is a significant adverse effect.
The anti-inflammatory drug diclofenac has shown in vitro antibacterial activity against E. coli strains resistant to common antibiotics, suggesting a potential role in treating urinary tract infections.

In conclusion, the treatment of E. coli infections involves a range of strategies including the use of non-pathogenic E. coli strains, immunomodulation, bacteriophage therapy, and various antibiotics tailored to the resistance patterns of the bacteria. The emergence of antibiotic-resistant strains of E. coli necessitates ongoing research into alternative treatments and the careful selection of antibiotics based on susceptibility testing.

How is E. coli infection treated?

Summary

Sources and full results

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

Non-pathogenic E. coli treatment is as effective as mesalazine in maintaining remission of ulcerative colitis, potentially providing clues to the cause of the condition.

E. coli infections of the lower urinary tract and their treatment by immunomodulation or combined immunomodulation and antigen therapy.

P40 treatment combined with antigen therapy effectively sterilizes urines in E. coli infections without causing prostate hypertrophy formation in rats.

Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli

Fosfomycin (97%), nitrofurantoin (94%), and pivmecillinam (85%) are effective oral treatment options for ambulatory patients with urinary tract infections caused by ESBL-producing Escherichia coli.

Bacteriophage Treatment of a Severe Escherichia coli Respiratory Infection in Broiler Chickens

Bacteriophage treatment is effective in reducing mortality in broiler chickens with severe E. coli respiratory infection when administered early and multiple treatments are better than single treatments.

SPREAD AND CONTROL OF ESCHERICHIA COLI DIARRHEAL DISEASE

Neomycin sulfate effectively controls E. coli diarrhea in infants, reducing cross-infection and allowing for a safe, effective nursery without significant cross-infection.

Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.

Fluoroquinolone-resistant Escherichia coli is a significant risk in patients with febrile urinary tract infection and sepsis after prostate biopsy, highlighting the need for alternative prophylactic antibiotics and treatment with cephalosporins.

Antibiotic resistance of E. coli in sewage and sludge.

E. coli in wastewater treatment plants show high resistance rates to various antibiotics, contributing to the dissemination of resistant bacteria in the environment.

Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Fosfomycin and amoxicillin-clavulanate are effective for cystitis caused by susceptible ESBL-producing E coli in predisposed patients.

Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Colistin may be a good therapeutic option for treating severe infections caused by multidrug-resistant P. aeruginosa and A. baumannii, with potential adverse effects including renal failure.

Diclofenac in the management of E. coli urinary tract infections.

Diclofenac shows potential as a treatment for E. coli urinary tract infections, as it is sensitive to clinically isolated strains and has the capacity to treat multidrug-resistant infections.

Try another search